Market revenue in 2024 | USD 47.0 million |
Market revenue in 2030 | USD 103.1 million |
Growth rate | 14% (CAGR from 2025 to 2030) |
Largest segment | Buprenorphine |
Fastest growing segment | Buprenorphine |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Buprenorphine, Methadone, Naltrexone |
Key market players worldwide | Indivior PLC Ordinary Share, Alkermes PLC, Titan Pharmaceuticals Inc, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, MediciNova Inc, Orexo AB, Camurus AB, Omeros Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to opioid use disorder market will help companies and investors design strategic landscapes.
Buprenorphine was the largest segment with a revenue share of 59.57% in 2024. Horizon Databook has segmented the South Korea opioid use disorder market based on buprenorphine, methadone, naltrexone covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea opioid use disorder market , including forecasts for subscribers. This country databook contains high-level insights into South Korea opioid use disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account